A phase 1b/2 study of the BET inhibitor ZEN003694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations Meeting Abstract

  

Authors:	Aftimos, P.; Oliveira, M.; Punie, K.; Boni, V.; Hamilton, E.; Gucalp, A.; Shah, P.; Mina, L.; Sharma, P.; Bauman, L.; Campeau, E.; Attwell, S.; Snyder, M.; Norek, K.; Czibere, A.; Yu, Y.; Silverman, M. H.; Lakhotia, S.; Domchek, S.; Litton, J.; Robson, M.
Abstract Title:	A phase 1b/2 study of the BET inhibitor ZEN003694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations
Meeting Title:	43rd Annual San Antonio Breast Cancer Symposium (2020 SABCS)
Journal Title:	Cancer Research
Volume:	81
Issue:	4 Suppl.
Meeting Dates:	2020 Dec 8-11
Meeting Location:	San Antonio, TX
ISSN:	0008-5472
Publisher:	American Association for Cancer Research
Date Published:	2021-02-01
Language:	English
ACCESSION:	WOS:000618737700336
PROVIDER:	wos
DOI:	10.1158/1538-7445.SABCS20-PS11-10
Notes:	Meeting Abstract: PS11-10 -- This symposium was held virtually due to COVID-19 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/179218